Method for producing activated polyethylene glycol having active group at terminal, and activated polyethylene glycol having active group at terminal
By reacting raw polyethylene glycol with a compound and a condensing agent, the method enhances the terminal activation rate of activated polyethylene glycol to 95% or more, addressing the inefficiencies of previous methods and reducing raw material usage and costs.
Patent Information
- Application Number
- PCT/JP2025/027290
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-05
- Filing Date
- 2025-08-01
- Publication Date
- 2026-02-12
AI Technical Summary
Existing methods for producing activated polyethylene glycol with a maleimide group at its terminal have low terminal activation rates, leading to increased raw polyethylene glycol usage and manufacturing costs.
A method involving the reaction of raw material polyethylene glycol with a compound having an active group and an amino group using a condensing agent, such as a triazine-based or uronium-based condensing agent, to achieve a terminal activation rate of 95% or more.
The method significantly increases the terminal activation rate of activated polyethylene glycol, reducing the amount of raw material needed and lowering manufacturing costs.
Smart Images

Figure JPOXMLDOC01-APPB-C000001 
Figure JPOXMLDOC01-APPB-C000002 
Figure JPOXMLDOC01-APPB-C000003
Abstract
Description
Method for producing activated polyethylene glycol having an active group at its terminal, and activated polyethylene glycol having an active group at its terminal
[0001] The present invention relates to a method for producing activated polyethylene glycol having an active group at its terminal, and to an activated polyethylene glycol having an active group at its terminal.
[0002] In recent years, in the pharmaceutical field, complexes formed by combining a protein active agent with a water-soluble composition have achieved improved efficacy compared to when the protein itself is injected into the body, due to factors such as an increased half-life and evasion of the immune system.
[0003] Polyethylene glycol is one of the water-soluble compositions used for protein binding. Generally, the formation of an active agent-polyethylene glycol conjugate is achieved by a reaction between the active agent and raw polyethylene glycol. To achieve this reaction, activated polyethylene glycol is used, in which the end of the raw polyethylene glycol is substituted with a reactive functional group (active group). However, if the terminal activation rate of the activated polyethylene glycol is low and a large amount of raw polyethylene glycol remains, more activated polyethylene glycol will be required during pharmaceutical manufacturing, which may result in increased variable costs. Therefore, it is necessary to minimize the amount of raw polyethylene glycol in the activated polyethylene glycol.
[0004] Various functional groups are used as reactive functional groups in activated polyethylene glycols, including the maleimide group, which is particularly effective in binding to thiol groups on proteins.
[0005] As an approach for producing activated polyethylene glycol having a maleimide group at its terminal, Patent Document 1 describes synthesis via polyethylene glycol having an electrophilic group at its terminal. According to the description in Patent Document 1, activated polyethylene glycol having a maleimide group is obtained by reacting a raw material polyethylene glycol having an electrophilic group containing a carboxy group with a maleimide compound having a nucleophilic group containing a primary amino group under favorable conditions.
[0006] Japan Special Table No. 2006-517600
[0007] Patent Document 1 includes an activated polyethylene glycol having a maleimide group. However, the method described in Patent Document 1 fails to increase the terminal activation rate of the activated polyethylene glycol.
[0008] Furthermore, as shown in Comparative Example 1 of Patent Document 1, it has been confirmed that the product obtained by reacting a terminally NHS-esterified polyethylene glycol with a maleimide compound having an amino group according to the method of Patent Document 1 has a terminal activation rate of less than 95% by mass.
[0009] An object of the present invention is to obtain activated polyethylene glycol having a high terminal activation rate by reacting a raw material polyethylene glycol having a terminal carboxy group with an activating reagent having an active group and an amino group at the terminals.
[0010] The present invention provides the following (1) to (8): (1) A method for producing activated polyethylene glycol having an active group at its terminal, comprising the step of reacting a raw material polyethylene glycol having a carboxy group with a compound having an active group and an amino group (sometimes referred to as an "activating reagent") using a condensing agent to obtain a reaction product containing activated polyethylene glycol having an active group at its terminal, wherein the terminal activation rate in the reaction product as analyzed by ion exchange chromatography is 95% by weight or more.
[0011] (2) The method according to (1), wherein the activated polyethylene glycol is represented by the following formula (1): PEG-(C═O)-NH-R formula (1) (in formula (1), PEG is a polyethylene glycol moiety, and R is an activated group).
[0012] (3) The method according to (1) or (2), wherein the active group is a maleimide group.
[0013] (4) The method according to any one of (1) to (3), wherein the condensing agent is a triazine-based condensing agent or a uronium-based condensing agent.
[0014] (5) The method according to any one of (1) to (4), wherein the raw material polyethylene glycol has a molecular weight of 100 to 100,000 daltons.
[0015] (6) The method according to any one of (1) to (5), wherein the starting polyethylene glycol has one or more functional groups selected from the group consisting of a hydroxy group, an azide group, a biotin group, a methoxy group, an aldehyde group protected with an acetal, an amino group protected with a 9-fluorenylmethyloxycarbonyl group, an amino group protected with a t-butoxycarbonyl group, and an amino group protected with a benzyloxycarbonyl group.
[0016] (7) An activated polyethylene glycol having an active group at its terminal, which is represented by the following formula (2), characterized in that the terminal activation rate as analyzed by ion exchange chromatography is 95% by weight or more: PEG-(C═O)-NH-R... formula (2) (in formula (2), PEG is a polyethylene glycol moiety, and R is an active group.)
[0017] (8) The activated polyethylene glycol according to (7), wherein the active group is a maleimide group.
[0018] According to the present invention, an efficient reaction between the carboxy group of the raw material polyethylene glycol and the amino group of the activating reagent, which was difficult to achieve with conventional techniques, is realized by selecting a specific condensing agent, and activated polyethylene glycol having a high terminal activation rate is successfully obtained.
[0019] (Activated Polyethylene Glycol) In the following section, the activated polyethylene glycol (hereinafter sometimes referred to as "activated PEG") produced in the present invention will be described.
[0020] The activated PEG of the present invention has a terminal activation rate of 95% or more. The activated PEG has the following formula (2): PEG-O-(C=O)-O-R (2) In formula (2), "PEG-" is a polyethylene glycol moiety having a linear, branched, or multi-arm structure, and R is an activated group.
[0021] The activated PEG of the present invention has an active group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, and the active group that forms this covalent bond is preferably one or more functional groups selected from the group consisting of a maleimide group, an azide group, a biotin group, an active ester group, an acetal-protected aldehyde group, a 9-fluorenylmethyloxycarbonyl-protected amino group, a t-butoxycarbonyl-protected amino group, and a benzyloxycarbonyl-protected amino group.
[0022] The activated PEG may have, at the end other than the activated end, a protecting group for a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, a hydroxyl group, or a hydrocarbon. The protecting group for a functional group that forms a covalent bond may be one or more functional groups selected from the group consisting of an aldehyde group protected with an acetal, an amino group protected with a 9-fluorenylmethyloxycarbonyl group, an amino group protected with a t-butoxycarbonyl group, and an amino group protected with a benzyloxycarbonyl group.
[0023] More specific examples of the activated PEG structure include activated PEGs represented by formulas (3) to (9). Among these, formulas (3) to (5) represent activated PEGs having a linear structure, formulas (6) to (8) represent activated PEGs having a branched structure, and formula (9) represents activated PEGs having a multi-arm structure.
[0024]
[0025] Here, X 1 is an atomic group containing a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, and Y 1is an atomic group that protects a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, and X 1 and atomic group Y 1 and the functional groups contained in R are different from each other; 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer of 3 to 2300; m is an integer of 1 to 1200; A 1 , A 2 , A 3 , A 4 are each independently -L 1 - (CH 2 ) m 1 -, -(CH 2 ) m 1 -L 1 -, -L 1 - (CH 2 ) m 1 -L 2 - (CH 2 ) m 2 represents - or a single bond, and L 1 represents an ether bond, an amide bond, a urethane bond, a secondary amino group, or a single bond; L 2 represents an ether bond, an amide bond or a urethane bond, m 1 and m 2 are each independently an integer of 0 to 5; 1 represents a carbon atom or a nitrogen atom.
[0026] [Method for Producing Activated PEG] The following describes a method for producing an activated PEG with activated terminals. The method for producing an activated PEG with activated terminals of the present invention includes a step of reacting a raw material polyethylene glycol having a carboxy group with a compound (activating reagent) having an active group and an amino group using a condensing agent to obtain a reaction product containing activated polyethylene glycol having an active group at its terminal.
[0027] Raw polyethylene glycol (sometimes referred to as "raw PEG") is a polymer synthesized by the polymerization reaction of ethylene glycol or ethylene oxide, and has at least a carboxy group.
[0028] The starting PEG has one or more carboxy groups. When starting PEG having one carboxy group is used as the starting material, a monovalent activated PEG is obtained, and when starting PEG having two carboxy groups is used as the starting material, a divalent activated PEG is obtained. Furthermore, when starting PEG having three or more carboxy groups is used as the starting material, a trivalent or higher activated PEG is obtained. In other words, the number of carboxy groups in the starting PEG determines the valence of the activated PEG. The number of carboxy groups in the starting PEG is preferably octavalent or less, and more preferably tetravalent or less.
[0029] The starting PEG is either monodisperse or polydisperse. Monodisperse PEG is characterized by a PEG purity of 90% or more and an impurity content of 2% or less, as described in Japanese Patent No. 6,638,970, and is a PEG of a single molecular weight without molecular weight distribution. Polydisperse PEG is a polymer of ethylene glycol, and unlike monodisperse PEG, has a molecular weight distribution. Polydisperse PEG useful as starting PEG is a polymer whose polydispersity is preferably 1.2 or less, more preferably 1.1 or less, and most preferably 1.03 or less.
[0030] The molecular weight of the starting PEG is preferably 100 to 100,000 daltons, more preferably 2,000 to 80,000 daltons, even more preferably 5,000 to 50,000 daltons, and even more preferably 10,000 to 40,000 daltons.
[0031] The starting PEG is particularly preferably a PEG having a linear structure, a branched structure or a multi-arm structure as shown in formulas (10) to (16).
[0032]
[0033] Here, Y 1 is an atomic group that protects a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond; R 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer of 3 to 2300; m is an integer of 1 to 1200; A 1 , A2 , A 3 , A 4 are each independently -L 1 - (CH 2 ) m 1 -, -(CH 2 ) m 1 -L 1 -, -L 1 - (CH 2 ) m 1 -L 2 - (CH 2 ) m 2 represents - or a single bond, and L 1 represents an ether bond, an amide bond, a urethane bond, a secondary amino group, or a single bond; L 2 represents an ether bond, an amide bond or a urethane bond, m 1 and m 2 are each independently an integer of 1 to 5; 1 represents a carbon atom or a nitrogen atom.
[0034] Exemplary solvents used in this production method include water, alcoholic solvents such as acetonitrile, DMSO, toluene, benzene, methanol, and ethanol, hydrocarbon solvents such as hexane and heptane, and chlorine-containing hydrocarbon solvents such as chloroform and dichloromethane. From the viewpoint of the solubility of the starting PEG, water, acetonitrile, DMSO, methanol, ethanol, toluene, chloroform, and dichloromethane are particularly preferred, and acetonitrile, methanol, and ethanol are more preferred. The solvent required in the present invention is one in which the starting PEG and activating reagent are partially or completely dissolved and the condensation reaction proceeds.
[0035] The active group of the activating reagent is an active group that reacts with a functional group present in a biofunctional molecule to form a covalent bond. The active group that forms this covalent bond is preferably one or more functional groups selected from the group consisting of a maleimide group, an azide group, a biotin group, an active ester group, an acetal-protected aldehyde group, a 9-fluorenylmethyloxycarbonyl-protected amino group, a t-butoxycarbonyl-protected amino group, and a benzyloxycarbonyl-protected amino group.
[0036] The condensing agent is a compound that promotes the condensation reaction between the starting polyethylene glycol having a carboxy group and a compound having an active group and an amino group.
[0037] Suitable condensing agents include uronium-based condensing agents and triazine-based condensing agents. Uronium-based condensing agents are condensing agents consisting of compounds containing a uronium structure, and include HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), HBTU (1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-oxide hexafluorophosphate), TATU (1-[bis(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide tetrafluoroborate), TBTU (1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-oxide tetrafluoroborate), and COMU ((1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate) are preferred, with HATU and COMU being particularly preferred. The triazine-based condensing agent is a condensing agent composed of a compound containing a triazine structure, and is preferably DMT-MM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) or (4,6-dimethoxy-1,3,5-triazin-2-yl)-(2-octoxy-2-oxoethyl)dimethylammonium trifluoromethanesulfonate, with DMT-MM being particularly preferred.
[0038] In this production method, if the active group of the activating reagent is a functional group that reacts with an amino group, the condensation reaction can be selectively carried out by using an amine hydrochloride activating reagent and adding a base to a solution containing the starting PEG having a carboxy group and the activating reagent having an amine hydrochloride. The base used in the reaction can be either an inorganic base or an organic base. However, the base must be selected based on its solubility in the solvent being used.
[0039] In this case, exemplary inorganic bases include sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, and disodium hydrogen phosphate. Among amine compounds commonly used as organic bases, primary and secondary amines may react with the activated PEG having active groups produced in this reaction, resulting in the production of impurities as by-products, so tertiary amines are more preferred. Exemplary tertiary amine bases include triethylamine, N-methylmorpholine, N-phenylmorpholine, N,N-diisopropylethylamine, pyridine, and 2,6-lutidine, with triethylamine and N,N-diisopropylethylamine being preferred.
[0040] Example 1 Compound (A) (Mw 4500, 500 mg, 0.11 mmol: starting PEG), compound (B) (33 mg, 0.13 mmol: activating reagent), N,N-diisopropylethylamine (22.7 μL, 0.13 mmol), and DMT-MM (85 mg, 0.31 mmol: condensing agent) were dissolved in acetonitrile (2.5 g) to obtain a solution. This solution was stirred for 2 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The obtained solid was dried to synthesize compound (C) (activated PEG). The terminal activation rate of the obtained product was measured by ion exchange chromatography, and was confirmed to be 96.6%.
[0041] Here, the terminal activation rate is defined as follows: Terminal activation rate = (mass of activated PEG in the product / mass of activated PEG in the product + mass of starting PEG).
[0042] To measure the terminal activation rate, 20 mg of formula (C) was dissolved in 2 mL of a labeling reagent, mercaptosuccinic acid aqueous solution (15 mg / mL). The mixture was then stirred at room temperature for 2 hours to allow the reaction to proceed. Next, the entire reaction solution was added to a gel filtration column (PD-10 (Amersham Biosciences)) equilibrated with the eluent used in HPLC measurements, and further eluent was added. The high molecular weight fraction that eluted first was collected in an HPLC measurement vial. Finally, HPLC measurements were performed under the following conditions.
[0043] The measurement conditions for ion exchange chromatography when measuring the terminal activation rate are as follows: (Ion exchange chromatography measurement conditions) HPLC apparatus: Alliance 6890 (Waters Co., Ltd.) Separation column: ES-502N (Asahipak) Eluent: 20 mM ammonium formate buffer (pH 8.0) Column temperature: 30°C Flow rate: 1.0 mL / min Sample concentration: 10 mg / mL Injection volume: 20 μL Detector: Differential refractometer (RI) (Waters Co., Ltd.)
[0044]
[0045]
[0046]
[0047] Example 2 Compound (D) (Mw 2000, 300 mg, 0.15 mmol: starting PEG), compound (B) (89 mg, 0.36 mmol: activating reagent), N,N-diisopropylethylamine (61.2 μL, 0.36 mmol), and DMT-MM (228 mg, 0.82 mmol: condensing agent) were dissolved in acetonitrile (1.5 g) to prepare a solution. This solution was stirred for 6 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (E) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, confirming a terminal activation rate of 97.5%. However, the concentration of the aqueous mercaptosuccinic acid solution was 30 mg / mL, and 80 mM ammonium formate buffer (pH 8.0) was used as the eluent.
[0048]
[0049]
[0050] Example 3 Compound (F) (Mw 5000, 500 mg, 0.10 mmol: starting PEG), compound (B) (30 mg, 0.12 mmol: activating reagent), N,N-diisopropylethylamine (20.4 μL, 0.12 mmol), and DMT-MM (76 mg, 0.27 mmol: condensing agent) were dissolved in acetonitrile (2.5 g) to form a solution. This solution was stirred for 6 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized from hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (G) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, and it was confirmed that the terminal activation rate was 96.1%.
[0051]
[0052]
[0053] Example 4 Compound (H) (Mw 10,000, 500 mg, 0.05 mmol: starting PEG), compound (B) (62 mg, 0.25 mmol: activating reagent), N,N-diisopropylethylamine (42.5 μL, 0.25 mmol), and DMT-MM (152 mg, 0.55 mmol: condensing agent) were dissolved in acetonitrile (3.5 g) to prepare a solution. This solution was stirred for 2 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (I) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, and it was confirmed that the terminal activation rate was 95.1%. However, the concentration of the aqueous mercaptosuccinic acid solution was 30 mg / mL, and 80 mM ammonium formate buffer (pH 8.0) was used as the eluent.
[0054]
[0055]
[0056] Example 5 Compound (J) (Mw 10,000, 500 mg, 0.05 mmol: starting PEG), compound (B) (15 mg, 0.06 mmol: activating reagent), N,N-diisopropylethylamine (10.2 μL, 0.06 mmol), and DMT-MM (38 mg, 0.14 mmol: condensing agent) were dissolved in acetonitrile (2.5 g) to prepare a solution. This solution was stirred for 4 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (K) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, and it was confirmed that the terminal activation rate was 95.1%. However, the concentration of the aqueous mercaptosuccinic acid solution was 15 mg / mL, and 1.5 mM ammonium formate buffer (pH 8.0) was used as the eluent.
[0057]
[0058]
[0059] Example 6 Compound (L) (Mw 40,000, 1.5 g, 0.038 mmol: starting PEG), compound (B) (11 mg, 0.044 mmol: activating reagent), N,N-diisopropylethylamine (42.5 μL, 0.044 mmol), and DMT-MM (30 mg, 0.11 mmol: condensing agent) were dissolved in acetonitrile (7.5 g) to prepare a solution. This solution was stirred for 4 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (M) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, confirming a terminal activation rate of 97.1%. However, the concentration of the aqueous mercaptosuccinic acid solution was 15 mg / mL, and 1.5 mM ammonium formate buffer (pH 8.0) was used as the eluent.
[0060]
[0061]
[0062] Example 6 Compound (L) (Mw 40,000, 1.5 g, 0.038 mmol: starting PEG), compound (B) (11 mg, 0.044 mmol: activating reagent), triethylamine (6.3 μL, 0.044 mmol), and DMT-MM (29 mg, 0.11 mmol: condensing agent) were dissolved in acetonitrile (7.5 g) to prepare a solution. This solution was stirred for 6 hours at 40°C under nitrogen. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized with hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (M) (activated PEG). The product was analyzed by ion exchange chromatography under the same conditions as in Example 1, confirming a terminal activation rate of 97.4%. However, the concentration of the aqueous mercaptosuccinic acid solution was 15 mg / mL, and 1.5 mM ammonium formate buffer (pH 8.0) was used as the eluent.
[0063] Comparative Example 1: The compound synthesized in Example 6 was synthesized using the method described in Patent Document 1. Compound (L) (Mw 40,000, 1.5 g, 0.038 mmol: starting PEG), N-hydroxysuccinimide (Mw 115.09, 13 mg, 0.11 mmol), and N,Ne'-dicyclohexylcarbodiimide (Mw 206.33, 16 mg, 0.08 mmol) were dissolved in acetonitrile (7.5 g) to obtain a solution. This solution was stirred for 3 hours under nitrogen at 40°C to synthesize compound (N). Subsequently, a solution of triethylamine (10.5 μL, 0.08 mmol) and compound (B) (11 mg, 0.044 mmol) was added to the reaction solution and stirred for 3 hours under nitrogen at 40°C. After the reaction, the solution was diluted with ethyl acetate (100 mL), crystallized from hexane (100 mL), and filtered. The resulting solid was dried to synthesize compound (M) (activated PEG). The product was measured by ion exchange chromatography under the same conditions as in Example 6, and it was confirmed that the terminal activation rate was 92.6%, which was less than 95%.
[0064]
[0065] In the present invention, activated polyethylene glycol having a high terminal activation rate can be obtained by reacting a raw material polyethylene glycol having a terminal carboxy group with an activating reagent having an active group and an amino group at the terminals.
[0066] Although the present invention has been described in detail and with reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the present invention. This application is based on a Japanese patent application (Patent Application No. 2024-128918) filed on August 5, 2024, the contents of which are incorporated herein by reference.
Claims
1. A method for producing activated polyethylene glycol having an active group at its terminal, comprising the step of reacting a raw material polyethylene glycol having a carboxy group with a compound having an active group and an amino group using a condensing agent to obtain a reaction product containing activated polyethylene glycol having an active group at its terminal, wherein the terminal activation rate in the reaction product as analyzed by ion exchange chromatography is 95% by weight or more.
2. The method for producing activated polyethylene glycol having an active group at its terminal, according to claim 1, wherein the activated polyethylene glycol is represented by the following formula (1): PEG-(C=O)-NH-R... formula (1) (In formula (1), PEG is a polyethylene glycol moiety, and R is an active group.) 3. A method for producing activated polyethylene glycol having an active group at its terminal according to claim 1 or 2, characterized in that the active group is a maleimide group.
4. A method for producing activated polyethylene glycol having an active group at its terminal according to claim 1 or 2, characterized in that the condensing agent is a triazine-based condensing agent or a uronium-based condensing agent.
5. A method for producing activated polyethylene glycol having terminal active groups according to claim 1 or 2, wherein the molecular weight of the raw material polyethylene glycol is 100 to 100,000 daltons.
6. The method for producing activated polyethylene glycol having an active group at its terminal according to claim 1 or 2, wherein the starting polyethylene glycol has one or more functional groups selected from the group consisting of a hydroxy group, an azide group, a biotin group, a methoxy group, an aldehyde group protected with an acetal, an amino group protected with a 9-fluorenylmethyloxycarbonyl group, an amino group protected with a t-butoxycarbonyl group, and an amino group protected with a benzyloxycarbonyl group.
7. An activated polyethylene glycol having an active group at its terminal, represented by the following formula (2), characterized in that the terminal activation rate as analyzed by ion exchange chromatography is 95% by weight or more: PEG-(C=O)-NH-R... formula (2) (In formula (2), PEG is a polyethylene glycol moiety, and R is an active group.) 8. The activated polyethylene glycol according to claim 7, wherein the active group is a maleimide group.
Citation Information
Patent Citations
Polyethylene glycol derivative capable of targeting hepatocytes and preparation method thereof
CN115028828A
Synthesis of high molecular weight non-peptidic polymer derivatives
JP2004525212A
Dissolvable hydrogel compositions for wound management and methods of use
WO2015002888A1